Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 302478947368420928.0% from a year ago
Other current liabilities stood at $344.83K at the end of Q1 FY2026, up 302478947368420928.0% from a year earlier.
Context
- Other current liabilities amounted to 6.0% of total assets at the end of Q1 FY2026, up 6.0 pp from a year earlier.
- Other current liabilities increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +302478947368420928.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $344.83K— QoQ
- Last fiscal yearDec 2025
- $0-100.0% YoY
- Year agoMar 2025
- $0+302478947368420928.0% since
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 527.38K | -9.4% |
| FY2022 | 2022-12-31 | 581.79K | +387.3% |
| FY2021 | 2021-12-31 | 119.4K | — |
Other Current Liabilities vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's Mar 2026 other current liabilities of $344.83K is the 5th highest of the 6 companies compared; the peer median is $1.23M.
- Its year-over-year change of +302478947368420928.0% is the highest of 6, against a peer median of -37.5%.
- Other current liabilities amounts to 6.0% of total assets for TELO, versus a peer median of 1.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.47M | +78.9% | -34.8% | 2.6% | |
| Mar 2026 | $1.94M | -37.5% | +6.0% | 0.6% | |
| Mar 2026 | $1.23M | +41.5% | -4.0% | 6.2% | |
| Mar 2026 | $1.13M | -49.7% | — | 1.8% | |
| Mar 2026 | $344.83K | +302478947368420928.0% | — | 6.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding TELO) | $1.23M | -37.5% | -4.0% | 1.8% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.